Eloralintide for Adults With Obesity Who Still Carry Excess Weight on a Weekly Incretin
Tests eloralintide against placebo in adults with obesity already taking a weekly incretin.
Plain-language title generated from the registry record
Registry title: A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
Key facts
- Where
- Botany, Box Hill, Brisbane, Camberwell, Geelong, Heidelberg West, Merewether, Oaklands Park, St Leonards, and Waitara, AustraliaSee the 10 sites
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with obesity or overweight who are already on a stable weekly incretin treatment. Some may also have type 2 diabetes.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Persistent obesity or overweight: BMI ≥30 kg/m2, or ≥27 kg/m2 with at least one obesity-related condition (high blood pressure, abnormal blood fats, sleep apnea, heart or blood vessel disease, or type 2 diabetes).
- Earlier treatment
- Must be on stable incretin therapy at screening. Must not have taken DPP-4 inhibitors, amylin analogs or insulin within 90 days before screening.
Main reasons for not taking part
- Prior or planned surgery for obesity (some procedures allowed if done more than 1 year before screening)
- Prior or planned endoscopic procedure or device-based obesity treatment (prior device allowed if removed more than 6 months before screening)
- Type 1 diabetes
- Heart attack, stroke, coronary artery revascularization, unstable angina or hospitalization for heart failure within 90 days before screening
- History of New York Heart Association Class IV congestive heart failure
Read by machine on 12 November 2026.
Where in Australia
- Emeritus ResearchBotany, AustraliaContact: Paul Bird (principal investigator)Taking people
- Box Hill HospitalBox Hill, AustraliaContact: Ming Li Yee (principal investigator)Taking people
- Royal Brisbane and Women's HospitalBrisbane, AustraliaContact: Donald McLeod (principal investigator)Taking people
- Emeritus ResearchCamberwell, AustraliaContact: Sam Francis (principal investigator)Taking people
- Barwon HealthGeelong, AustraliaContact: Kay Hau (Aaron) Choy (principal investigator)Taking people
- Austin Health - Repatriation HospitalHeidelberg West, AustraliaContact: Elif Ekinci (principal investigator)Taking people
- Aim ResearchMerewether, AustraliaContact: Claire Morbey (principal investigator)Taking people
- Southern Adelaide Diabetes & Endocrine ServicesOaklands Park, AustraliaContact: Jui Ho (principal investigator)Taking people
- Royal North Shore HospitalSt Leonards, AustraliaContact: Sarah Glastras (principal investigator)Taking people
- Innovate Clinical ResearchWaitara, AustraliaContact: Rachel Graham (principal investigator)Taking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Eli Lilly and Company
- Trial code
- NCT07392190EU 2025-523659-73-00
- Record updated
- 4 November 2026
- Original description
The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo in participants with persistent obesity or overweight, with or without type 2 diabetes, and on stable incretin background therapy.Read full original descriptionShow less
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Persistent Obesity or Overweight Treated With a Weekly Incretin, With and Without Type 2 Diabetes
The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo in participants with persistent obesity or overweight, with or without type 2 diabetes, and on stable incretin background therapy.
Participation in the study will last about 80 weeks.
Inclusion: Are on stable incretin therapy at screening; With persistent obesity or overweight defined as:; ≥30 kg/m2 OR; ≥27 kg/m2 with at least one existing obesity related complication at screening:; hypertension; dyslipidemia; obstructive sleep apnea; cardiovascular disease (for example, ischemic cardiovascular disease, New York Heart Association Functional Class I-III heart failure), or; type 2 diabetes; Have a stable body weight (<5% body weight change) at screening.
Exclusion: Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed >1 year before screening); Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening); Have taken any of the following antihyperglycemic medications within 90 days before screening:; dipeptidyl peptidase-4 (DPP-4) inhibitors; amylin analogs; insulin; Have had within 90 days prior to screening:; heart attack; stroke; coronary artery revascularization; unstable angina, or; hospitalization due to congestive heart failure; Have type 1 diabetes; Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure.